Blog da pesquisa
Resumos em linguagem simples de novos estudos sobre HSV, resultados de estudos clínicos e decisões regulatórias. Cada post traz o link da fonte original.
Fred Hutch’s Keith Jerome on the road to a herpes cure
The scientist leading the best-known HSV gene-therapy program sat down to talk cure research. Here’s the background that makes the conversation worth your time.
Ler o resumo
Moderna posts results for its therapeutic HSV‑2 vaccine
Results from the Phase 1/2 study of mRNA‑1608 in adults with recurrent genital herpes are now public. Here’s what the trial was designed to answer.
Ler o resumo
Long-acting herpes pills finish Phase 1b
Assembly Bio completed follow-up for its two helicase-primase inhibitors. The headline number: 94% fewer days of viral shedding than placebo.
Ler o resumo
FDA fast-tracks review of pritelivir
If approved, it would be the first new HSV treatment in more than 20 years. A decision is due by the end of 2026.
Ler o resumo
Gilead licenses Assembly Bio’s herpes program
After positive early data, one of the world’s largest antiviral companies takes over development of two long-acting herpes drugs.
Ler o resumo
A simpler, safer gene therapy for herpes
Fred Hutch reported that a streamlined gene-editing treatment removed 90% or more of HSV‑1 in mice, with fewer side effects.
Ler o resumoReceba a próxima novidade no seu e-mail
Um e-mail por avanço relevante. Cancele quando quiser.
Receba novidades da pesquisa
Seu nome e e-mail. Só isso.